These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17570565)

  • 1. Clinical hypothesis: Application of AIDS vaccines together with thyroid hormones to increase their immunogenic effect.
    Halabe Bucay A
    Vaccine; 2007 Aug; 25(33):6292-3. PubMed ID: 17570565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.
    Liu J; Ngai N; Stone GW; Yue FY; Ostrowski MA
    Vaccine; 2009 Aug; 27(37):5077-84. PubMed ID: 19573639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines as adjuvants for improving anti-HIV responses.
    Morrow MP; Weiner DB
    AIDS; 2008 Jan; 22(3):333-8. PubMed ID: 18195559
    [No Abstract]   [Full Text] [Related]  

  • 4. Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
    Bråve A; Hallengärd D; Schröder U; Blomberg P; Wahren B; Hinkula J
    Vaccine; 2008 Sep; 26(40):5075-8. PubMed ID: 18450334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.
    Ahlers JD; Belyakov IM
    Trends Mol Med; 2009 Jun; 15(6):263-74. PubMed ID: 19487159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel adjuvants and delivery systems for HIV vaccines.
    O'Hagan DT; Lavelle E
    AIDS; 2002; 16 Suppl 4():S115-24. PubMed ID: 12699008
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells.
    Hinkula J; Walther-Jallow L; Laurén A; Mäkitalo B; Oberg M; Wahren B; Fenyö EM; Spetz AL
    Vaccine; 2009 Oct; 27(46):6424-31. PubMed ID: 19549607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines.
    Ozpolat B; Lachman LB
    Methods Enzymol; 2003; 373():92-100. PubMed ID: 14714398
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting.
    Li W; Li S; Hu Y; Tang B; Cui L; He W
    Vaccine; 2008 Jun; 26(26):3282-90. PubMed ID: 18472194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Could a nasal spray protect people against human immunodeficiency virus?
    Bull World Health Organ; 1999; 77(12):1017-8. PubMed ID: 10712065
    [No Abstract]   [Full Text] [Related]  

  • 12. Key issues for a potential human immunodeficiency virus vaccine.
    Hu DJ; Vitek CR; Bartholow B; Mastro TD
    Clin Infect Dis; 2003 Mar; 36(5):638-44. PubMed ID: 12594646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of multicomponent DNA vaccination strategies against HIV.
    Kim JJ; Weiner DB
    Curr Opin Mol Ther; 1999 Feb; 1(1):43-9. PubMed ID: 11249683
    [No Abstract]   [Full Text] [Related]  

  • 14. Delaying the immune-suppressive function of regulatory T cells might enhance immune responses against HIV vaccines.
    Immunotherapy; 2010 May; 2(3):301. PubMed ID: 20658753
    [No Abstract]   [Full Text] [Related]  

  • 15. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for optimizing targeting and delivery of mucosal HIV vaccines.
    Ahlers JD; Belyakov IM
    Eur J Immunol; 2009 Oct; 39(10):2657-69. PubMed ID: 19609978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal immune status influences HIV-specific immune responses in pups after DNA prime protein boost using mucosal adjuvant.
    Bråve A; Johansen K; Palma P; Benthin R; Hinkula J
    Vaccine; 2008 Nov; 26(47):5957-66. PubMed ID: 18801400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
    Turbant S; Martinon F; Moine G; Le Grand R; Léonetti M
    Vaccine; 2009 Aug; 27(39):5349-56. PubMed ID: 19607953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of an AIDS vaccine: status report].
    Girard MP
    Med Trop (Mars); 2007 Aug; 67(4):340-6. PubMed ID: 17926791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.